Emerging evidence suggests that activation of the complement system is critical in the pathogenesis of the novel coronavirus, SARS‐CoV‐2, the causative agent of COVID‐19 related lung injury. Inhibition of the terminal complement pathway by targeting complement protein 5 (C5) may be an effective therapeutic intervention in CoV‐mediated disease.(1) Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired hematopoietic stem cell (HSC) disease characterized by intravascular haemolysis, increased thromboembolic risk and bone marrow failure.(2)